In this regard, despite that initial studies recognized its chemopreventive function in carcinogenesis and its cytoprotective role in many human pathologies [120–123], growing evidence also indicates that aberrant activation of the NRF2/KEAP1 pathway is frequently found in many tumors, promoting cancer growth [6, 10, 14], survival [124, 125], metastasis formation [11, 126, 127], and therapy resistance [20, 21, 128–132]. The gene discussed is NFE2L2; the disease is cancer.